As a caregiver, I learned that CyberKnife radiation for metastatic prostate cancer comes with psychological and physical ...

The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...

ABOUT 55,000 new prostate cancer cases are recorded every year in the UK. Bladder cancer is less common, with around 10,500 ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

Symptoms of prostate cancer may include needing to urinate more frequently; having to rush to the toilet; straining to ...

Lenny Santoro was diagnosed with prostate cancer in 2011. Thanks to clinical trials Santoro participated in at the Duke ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor pathway inhibitor.

OncoHelix, a leader in precision diagnostics, is proud to announce its partnership with AstraZeneca Canada to deliver cutting-edge liquid biopsy testing for men with metastatic castration-resistant ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...